TRIAL DATA
Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancerA study examined dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H metastatic colorectal cancer, reporting early survival benefit and exploratory clinical predictors. (Clinical Colorectal Cancer)